Lipidic drug delivery systems are responsive to the human microbiome.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Academic Press Country of Publication: United States NLM ID: 0043125 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-7103 (Electronic) Linking ISSN: 00219797 NLM ISO Abbreviation: J Colloid Interface Sci Subsets: MEDLINE
    • Publication Information:
      Publication: Orlando, FL : Academic Press
      Original Publication: New York.
    • Subject Terms:
      Staphylococcus aureus*/drug effects ; Microbiota*/drug effects ; Drug Delivery Systems*; Humans ; Glycerides/chemistry ; Drug Liberation ; Lipids/chemistry ; Nanostructures/chemistry ; Drug Carriers/chemistry ; Particle Size
    • Abstract:
      In vitro and in vivo tests for therapeutic agents are typically conducted in sterile environments, but many target areas for drug delivery are home to thousands of microbial species. Here, we examine the behaviour of lipidic nanomaterials after exposure to representative strains of four bacterial species found in the gastrointestinal tract and skin. Small angle X-ray scattering measurements show that the nanostructure of monoolein cubic and inverse hexagonal phases are transformed, respectively, into inverse hexagonal and inverse micellar cubic phases upon exposure to a strain of live Staphylococcus aureus often present on skin and mucosa. Further investigation demonstrates that enzymatic hydrolysis and cell membrane lipid transfer are both likely responsible for this effect. The structural responses to S. aureus are rapid and significantly reduce the rate of drug release from monoolein-based nanomaterials. These findings are the first to demonstrate how a key species in the live human microbiome can trigger changes in the structure and drug release properties of lipidic nanomaterials. The effect appears to be strain specific, varies from patient to patient and body region to body region, and is anticipated to affect the bioapplication of monoglyceride-based formulations.
      Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Wye-Khay Fong reports financial support was provided by Noxopharm Limited. Jonathan Caukwell reports financial support was provided by Australian Nuclear Science and Technology Organisation. Salvatore Assenza reports financial support was provided by LaCaixa Foundation. Salvatore Assenza reports financial support was provided by European Commission Marie Sklodowska-Curie Actions. Salvatore Assenza reports financial support was provided by Spanish Scientific Research Council. Livia Salvati Manni reports financial support was provided by Swiss National Science Foundation. Karl Hassan, Brett Neilan reports financial support was provided by Australian Research Council. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Drug delivery systems; Lipid mesophase; Lipid-cubic phase; Microbiome; Monoolein; Nano-biome interactions; Nanomaterials; Nanotherapeutics; Response to physiological stimuli
    • Accession Number:
      0 (Glycerides)
      C4YAD5F5G6 (monoolein)
      0 (Lipids)
      0 (Drug Carriers)
    • Publication Date:
      Date Created: 20240815 Date Completed: 20241011 Latest Revision: 20241011
    • Publication Date:
      20241011
    • Accession Number:
      10.1016/j.jcis.2024.07.216
    • Accession Number:
      39146817